March 15, 2017
OptiBiotix confimrs new board members
OptiBiotix has confirmed today that Per Rehné and Christina Wood have been appointed to the Board of OptiBiotix. The company in January announced naming the new members.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
March 14, 2017
Tiziana Life Sciences welcomes liver specialist to its Scientific Advisory Board
Tiziana Life Sciences, a clinical stage biotechnology company developing targeted drugs for cancer, autoimmune and inflammatory diseases, has appointed Dr. Arun Sanyal as a new member of its Scientific Advisory Board.
March 14, 2017
FDA OK’s Novartis’s breast cancer drug
The US Food and Drug Administration (FDA) has approved Novartis’s Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
March 13, 2017
Ipsen wins MHRA’s approval for its breast cancer drug
Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, in coordination with fourteen other European regulatory agencies, has approved a new indication for Ipsen’s Decapeptyl as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy.
March 13, 2017
GenSight Biologics reports €22M loss for 2016
GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, has reported €22.1 million loss for 2016, which is increase of loss comparing last years €13.7 million.
March 13, 2017
Virbac reports 268% net profit increase
Virbac has reported net profit of €34.6 million for 2016 which is 268% increase compared to 2015.
March 13, 2017
TiGenix’s hearth attack study confirms the long term safety
TiGenix has found in its acute hearth attack study that allogenic cardiac stem cells can be transplanted safely through the coronary tree.
March 13, 2017
Innate Pharma and BMS modify clinical trial protocol for cancer testing
Innate Pharma and Bristol-Myers Squibb have modified the clinical trial protocol for its ongoing Phase I/II trial evaluating the safety and tolerability of lirilumab in combination with Opdivo in patients with advanced refractory solid tumors.
March 10, 2017
Oxfor Pharmascience reduces loss year over year with less clinical trials
Oxford Pharmascience Group has posted full year loss before tax £1.9m, compared to 2015’s £3.9m, citing lower number of clinical…
March 10, 2017
Galapagos trying JAK1 inhibitor filgotinib in two types Chron’s disease
Galapagos NV has started two new Phase 2 studies of filgotinib in small bowel Crohn`s disease and in fistulizing Crohn`s disease, both led by filgotinib collaboration partner Gilead Sciences.